Palvella Therapeutics
PVLA
130.59
+2.59
+2.02%
Palvella Therapeutics
US · PVLA
#2822 by market cap
Listed 1970
130.59
+2.59
+2.02%
Live - 5344 symbols - heartbeat 429s ago
· 2026-10-08 04:00
Pre-market
131.00
+0.31%
After-hours
130.70
+0.08%
Overnight
130.05
-0.41%
- Market cap
- 1.88B
- P/E (TTM)i
- -26.93
- P/Bi
- 8.68
- EPSi
- -3.71
- Div yieldi
- 0.00%
- 52W posi
- 68%
Reader sentiment
Are you bullish or bearish on PVLA?
Anonymous reader poll. Unscientific, not investment advice.
Analyst consensus 9 analysts
Buy
Avg price target
235.22 +80.1%
Price target rangecurrent 130.59
Low207.00
Avg235.22
High270.00
Buy 100%
Hold 0%
Sell 0%
Recent ratings (25)
| Date | Firm | Analyst | Rating | Target |
|---|---|---|---|---|
| 2026-09-21 | Chardan Capital | -- | BUY | 240.00 |
| 2026-09-10 | Mizuho Securities | -- | BUY | 240.00 |
| 2026-08-31 | Mizuho Securities | -- | BUY | 240.00 |
| 2026-08-05 | CCORF | -- | BUY | 232.00 |
| 2026-08-05 | LifeSci Capital | -- | BUY | 236.00 |
| 2026-08-05 | Truist Financial | -- | BUY | 207.00 |
| 2026-08-05 | H.C. Wainwright | -- | BUY | 270.00 |
| 2026-08-05 | Oppenheimer | -- | BUY | 210.00 |
| 2026-08-04 | TD Cowen | -- | BUY | 267.00 |
| 2026-08-04 | BTIG | -- | BUY | 215.00 |
| 2026-07-21 | TD Cowen | -- | BUY | 267.00 |
| 2026-07-21 | H.C. Wainwright | -- | BUY | 270.00 |
| 2026-07-21 | Oppenheimer | -- | BUY | 210.00 |
| 2026-07-20 | CCORF | -- | BUY | 227.00 |
| 2026-07-20 | LifeSci Capital | -- | BUY | 225.00 |
| 2026-07-20 | BTIG | -- | BUY | 215.00 |
| 2026-07-17 | TD Cowen | -- | BUY | 157.24 |
| 2026-07-01 | Mizuho Securities | -- | BUY | 240.00 |
| 2026-06-25 | CCORF | -- | BUY | 227.00 |
| 2026-06-24 | Stifel | -- | BUY | 250.00 |
| 2026-06-22 | Craig-Hallum | -- | BUY | 205.00 |
| 2026-06-11 | H.C. Wainwright | -- | BUY | 270.00 |
| 2026-06-04 | Mizuho Securities | -- | BUY | 240.00 |
| 2026-06-04 | H.C. Wainwright | -- | BUY | 270.00 |
| 2026-05-27 | Mizuho Securities | -- | BUY | 240.00 |
Quant vs Street three independent views, side by side
Momentum strategy signal
Buy
Analyst consensus
Buy
All 2 views agree: bullish.
Not investment advice. The factor grade ranks this stock on fundamentals against StockVane's covered universe; the momentum strategy signal is a rules-based backtest, not a recommendation; analyst consensus reflects sell-side coverage. The three use different methods and can reasonably disagree.
Price target trend monthly average, last 3 years
Earnings history price reaction on the day
| Period | Report date | Session | Options expected | Actual move |
|---|---|---|---|---|
| 2026/Q2 | 2026-08-04 | -- | ±11.09% | +7.96% (in line) |
| 2026/Q1 | 2026-05-07 | -- | ±8.37% | -12.99% (beat) |
| 2025/Q4 | 2026-03-31 | -- | ±12.16% | +12.64% (beat) |
| 2025/Q3 | 2025-11-11 | -- | ±9.99% | -3.04% (in line) |
| 2025/Q2 | 2025-08-14 | -- | -- | +3.27% |
| 2025/Q1 | 2025-05-15 | -- | -- | -0.41% |
| 2024/Q4 | 2025-03-31 | -- | -- | -0.39% |
"Options expected" is the pre-earnings options market's implied move (a straddle-style estimate), shown next to what actually happened.
Quote time 2026-10-08 04:00:14 · For reference only, not investment advice and not tailored to your situation.